Product Description: Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia[1][2].
Applications: Metabolism-protein/nucleotide metabolism
Formula: C40H56ClN3O4S
References: [1]Shirley M. Maralixibat: First Approval [published correction appears in Drugs. 2021 Dec 6;:]. Drugs. 2022;82(1):71-76./[2]Mayo MJ, et al. A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatol Commun. 2019 Feb 1;3(3):365-381.
CAS Number: 228113-66-4
Molecular Weight: 710.41
Compound Purity: 99.08
Research Area: Metabolic Disease
Solubility: DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Apical Sodium-Dependent Bile Acid Transporter
English
Deutsch
